SyBridge Technologies Completes Acquisition Of X-Cell Tool And Mold, Inc.

SyBridge Technologies (Southfield, Michigan) a global technological leader in the tooling and mold industry, announced today that it has completed the acquisition of X-Cell Tool and Mold, Inc. (X-Cell, Fairview, Pennsylvania). This transaction marks the first acquisition by SyBridge in the medical tooling industry and supplements SyBridge's presence in the mobility end market through its Concours Technologies subsidiary. New York-based private equity firm, Crestview Partners, established SyBridge Technologies in 2019 and committed $200 million of equity to create a market leader spanning across end markets, geographies and advanced technological capabilities to provide value-added manufacturing solutions to its customers.

X-Cell is a manufacturer of close-tolerance and multi-cavity plastic injection molds primarily for the medical industry while also serving the consumer goods and electronics industries. The company was founded in 1996 and utilizes state-of-the-art engineering and manufacturing capabilities to provide precise and effective customer tooling.

X-Cell also retains a host of recognitions, including the Amerimold 2019 Leadtime Leader award, which awards outstanding moldmakers who best demonstrate overall innovation, efficiency, quality and commitment. Further, the company is well-known for its consistent investment, not only in its customers, but in optimizing its five-axis machining capabilities, as well as its focus on continuously improving; Brian Dippler, is also currently on MMT’s Editorial Advisory Board (EAB) for 2020.   

The acquisition of X-Cell is said to expands SyBridge's tooling capabilities to include highly complex precision tooling solutions necessary for the medical industry. As a part of SyBridge, X-Cell will be able to leverage design, engineering, supply chain and production capabilities to better serve and grow with its customers.

"X-Cell is a strong beginning to SyBridge building a leading franchise in the medical tooling industry," says Tony Nardone, CEO of SyBridge. "Through continuing to grow with new and existing customers and targeted acquisitions which will complement X-Cell, we are highly optimistic about our growth prospects within the medical industry."

Ron Novel, CEO of X-Cell, adds that the company is a terrific addition to SyBridge. "We are proud to become the anchor for a new medical business unit. Becoming part of SyBridge is a win-win situation for X-Cell and our employees and we look forward to accelerating growth and expanding our ability to service our customers as part of SyBridge."

To get to know X-Cell Mold and Tool a little better, MoldMaking Technology suggests the content below:

• Leadtime Leader Q&A: X-Cell Tool and Mold
• Leadtime Leader Q&A: X-Cell Tool and Mold on Automation
• Leadtime Leader Q&A: X-Cell Tool and Mold on Quality Assurance
• VIDEO: X-Cell Tool and Mold Is MoldMaking Technology's 2019 Leadtime Leader Award Winner